Muscle Stimulator Market Segmentation:
Product Segment Analysis
The transcutaneous electrical nerve stimulator segment is predicted to dominate about 38% market share by 2035. The segment growth can be attributed to increasing prevalence of rheumatoid arthritis. A chronic, systemic, inflammatory condition known as rheumatoid arthritis (RA) primarily affects the synovial membranes of many bodily joints, most likely caused by a mix of genetic predisposition, numerous environmental circumstances, and a person's lifestyle. Inflammatory arthritis, such as rheumatoid arthritis, may also be treated using transcutaneous electrical nerve stimulator (TENS). As part of an arthritis self-management plan, it is affordable, safe, and simple to use. Further, the discomfort associated with rheumatoid arthritis is frequently managed by transcutaneous electrical nerve stimulation. According to estimates, rheumatoid arthritis affects approximately 1% of people globally.
Application Segment Analysis
The pain management segment is expected to garner around 46% market share by 2035. Aches in the muscles are a common occurrence in all ages and occupations, which can result from a known injury, illness, or a medical procedure. Additionally, acute pain may result from injuries such as cuts, burns, muscle strains, and others, whereas chronic pain can be caused by disease such as arthritis or cancer. Further, muscle stimulators are being used more often to treat both acute and long-term pain. For instance, transcutaneous electrical nerve stimulation (TENS) is a low-cost nonpharmacological therapy for acute and chronic pain disorders. TENS units send electrical impulses that block pain by resembling the nervous system's pain signals.
Our in-depth analysis of the global market includes the following segments:
|
By Application |
|
|
By Product |
|
|
By End User |
|
|
By Modality |
|
